Format

Send to

Choose Destination
J Natl Cancer Inst. 2013 Sep 18;105(18):1417-20. doi: 10.1093/jnci/djt225. Epub 2013 Aug 29.

Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment.

Author information

1
Affiliations of authors: University of Texas MD Anderson Cancer Center, Houston, TX (MIH); Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY (IG); Institut Gustave Roussy, Villejuif, France (SL); Yale School of Medicine, New Haven, CT (KI); Montefiore Medical Center-Bronx, New York, NY (RG); Endocrinology Department, Medical Center for Postgraduate Education, Warsaw, Poland (WM); Peninsula Regional Medical Center, Salisbury, MD (BY); Amgen Inc., Thousand Oaks, CA, USA (WY, RKJ).

Abstract

Hypercalcemia of malignancy (HCM), caused primarily by tumor-induced bone resorption, may lead to renal failure, coma, and death. Although HCM can be treated with intravenous bisphosphonates, patients may not respond or may relapse on therapy. Denosumab binds the bone resorption mediator RANKL. In this single-arm, open-label, proof-of-concept study, HCM patients with albumin-corrected serum calcium (CSC) levels greater than 12.5mg/dL (Common Terminology Criteria for Adverse Events grade ≥ 3) despite recent intravenous bisphosphonate treatment received subcutaneous denosumab on days 1, 8, 15, and 29, and then every 4 weeks. The primary endpoint was the proportion of patients with CSC 11.5mg/dL or less (grade ≤ 1) within 10 days of denosumab initiation. In a prespecified interim analysis, 15 patients received denosumab (median CSC = 13.6 mg/dL). Time to response and response duration were analyzed with Kaplan-Meier methods. All statistical tests were two-sided. By day 10, 12 patients (80%; 95% exact confidence interval [CI] = 52% to 96%) responded (CSC ≤ 11.5mg/dL); median response duration was 26 days. Ten patients (67%; 95% exact CI = 38% to 88%) had complete responses (CSC ≤ 10.8 mg/dL) by day 10. Denosumab may offer a new treatment option for HCM. Clinicaltrials.gov identifier: NCT00896454.

PMID:
23990665
PMCID:
PMC3776443
DOI:
10.1093/jnci/djt225
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center